WallStSmart

Boston Scientific Corp (BSX)vsRapid Micro Biosystems Inc (RPID)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 59667% more annual revenue ($20.07B vs $33.59M). BSX leads profitability with a 14.4% profit margin vs -140.3%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

RPID

Avoid

33

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -5.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for RPID.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

RPID1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37.3%10/10

Revenue surging 37.3% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

RPID4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$104.56M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-86.8%2/10

ROE of -86.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : RPID

The strongest argument for RPID centers on Revenue Growth. Revenue growth of 37.3% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : RPID

The primary concerns for RPID are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

BSX profiles as a growth stock while RPID is a hypergrowth play — different risk/reward profiles.

RPID carries more volatility with a beta of 1.39 — expect wider price swings.

RPID is growing revenue faster at 37.3% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 33/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Rapid Micro Biosystems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Rapid Micro Biosystems Inc is an innovative biotechnology company focused on revolutionizing microbiological quality control for the pharmaceutical and biotechnology industries. Utilizing advanced automated growth-based microbial detection technologies, the firm significantly improves the precision and efficiency of microbial testing, ensuring high product quality and regulatory compliance. With an increasing demand for rapid, reliable quality control solutions in regulated environments, Rapid Micro is well-positioned to meet these urgent market needs and lead the evolution of microbiological testing methodologies.

Visit Website →

Want to dig deeper into these stocks?